Skip to content
Sunday, April 2, 2023
HealthCare Middle East & Africa Logo 500

No.1 Healthcare & Pharma Industry Magazine for Middle East & Africa

  • HOME
  • TOPICS
    • MERGERS, INVESTMENTS & FUNDING
    • DISEASES UPDATES
    • HOSPITALS
    • PHARMACEUTICALS
    • PEOPLE NEWS
  • THE MAGAZINE
    • About HealthCare Middle East & Africa Magazine
    • PRESS RELEASES
    • SUBSCRIBE TO EMAIL NEWSLETTERS
  • ADVERTISE
  • PROFILES & INTERVIEWS
  • OUR EVENTS
  • CONTACT US
BREAKING NEWS
  • Amanat Holdings unveils its single platform Amanat Healthcare
  • Fujifilm expands its endoscopy portfolio with the launch of CAD EYE Upper GI in India
  • Redcliffe Labs snaps up Indian diagnostics chain Medicentre Sonography & Clinical Lab
  • JICA signs US$330M loan agreement for Egypt's road to universal health insurance
  • New manufacturing unit to open at the VASCERA complex in Egypt
  • WHO steps up healthcare response for Somali refugees in Ethiopia's Dollo Zone
  • Zanzibar's health sector gets a boost as EAC launches health scorecard for maternal and child health
  • Kenya to commence local production of drugs and vaccines in collaboration with Belgium company
  • Dr. Moopen’s family invests US$56M in Aster DM Healthcare, raises stake to 41.88%
  • Takeda ramps up production capacity for plasma-derived therapies with US$765M investment in Japanese facility
You are here
  • Home
  • Novo Nordisk

Tag: Novo Nordisk

FDA removes most doses of Ozempic from drug shortage list after Novo Nordisk resolves supply issues

21 March 202322 March 2023

USA — Novo Nordisk’s Ozempic, a treatment for type 2 diabetes and off-label for weight loss, is no longer on the FDA’s drug shortage list after months of limited supply.…

Read More

ABPI takes action against Novo Nordisk for violating code with Saxenda LinkedIn promotion

17 March 202317 March 2023

UNITED KINGDOM — Novo Nordisk has been suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) for two years due to “serious breaches” of the trade…

Read More

Insulin affordability in focus: Novo Nordisk and Eli Lilly lower prices in the US

15 March 202316 March 2023

USA — Novo Nordisk has followed in the footsteps of Eli Lilly by announcing a reduction in the prices of its insulin products in the United States two weeks after…

Read More

EMA issues warning on Ozempic shortage and potential risks for diabetes patients

15 March 202315 March 2023

NETHERLANDS — The European Medicines Agency (EMA) has urged doctors to prioritize the diabetes drug Ozempic, manufactured by Novo Nordisk, for patients with diabetes who may be at risk if…

Read More

Former Novo Nordisk vice chair to step down

24 February 202324 February 2023

DENMARK — Novo Nordisk has announced that Jeppe Christiansen will not stand for re-election as member of the Board at the AGM to be held on 23 March 2023. The…

Read More

Novo Nordisk celebrates 100th global anniversary in India, to launch a once-a-week insulin shot

17 February 202317 February 2023

INDIA – Danish pharma giant Novo Nordisk has celebrated its 100th global anniversary with a special event in Bangalore, India. The major milestone comes at a point in time when…

Read More

Novo Nordisk apologizes for undisclosed sponsorship of anti-obesity training

14 February 202314 February 2023

DENMARK — Novo Nordisk’s CEO has apologized for breaching the UK industry code by not disclosing its sponsorship of obesity and weight management courses for healthcare professionals that also promoted…

Read More

ABPI president steps down over Novo Nordisk breach of trade group’s code

12 February 202313 February 2023

UNITED KINGDOM —The president of the Association of the British Pharmaceutical Industry (ABPI) and UK head of Novo Nordisk, Pinder Sahota, has resigned from the role at the association after…

Read More

FDA approves Novo Nordisk’s diabetes pill as first-line therapy

16 January 202316 January 2023

USA — The US Food and Drug Administration (FDA) has approved a label update for Novo Nordisk’s oral semaglutide (Rybelsus) allowing the agent to be used as an initial treatment…

Read More

Novo Nordisk expands partnership with Amalgam Rx on connected insulin delivery devices

21 December 202221 December 2022

DENMARK —Novo Nordisk has expanded its collaboration with Amalgam Rx, a US-based company to support the commercialization of Dose Check, a digital insulin initiation and titration app. Dose Check digital…

Read More

Posts navigation

Older posts

LATEST DIGITAL MAGAZINE

LATEST NEWS

  • Amanat Holdings unveils its single platform Amanat Healthcare
  • Fujifilm expands its endoscopy portfolio with the launch of CAD EYE Upper GI in India
  • Redcliffe Labs snaps up Indian diagnostics chain Medicentre Sonography & Clinical Lab
  • JICA signs US$330M loan agreement for Egypt’s road to universal health insurance
  • New manufacturing unit to open at the VASCERA complex in Egypt

MOST POPULAR TAGS

Africa Africa CDC Artificial Intelligence AstraZeneca Cancer Covid-19 Diabetes Digital health Egypt France Germany Ghana GSK Healthcare Delivery HIV/AIDS Hospitals India Japan Johnson & Johnson Kenya Malaria Merck Mergers, Investments & Funding Middle East and North Africa Moderna MOH Kenya Nigeria Novartis Partnerships Pfizer Pharmaceuticals Public Health Roche Science & Technology South Africa Switzerland Tanzania UAE Uganda UK UNICEF USA US FDA Vaccines WHO

ARCHIVES

ABOUT FW AFRICA

We organise some of the most impactful face to face and virtual trade events and publish leading magazines and websites that bring Africa to the World and the World to Africa. We believe that when people come together, networks grow and businesses thrive.

Find more about us on our corporate website www.fwafrica.net

RELATED PUBLICATIONS

Food Business Africa

Food Safety Africa

Milling Middle East & Africa

Sustainable Packaging Africa

CEO Business Africa

CONTACT US

FW Africa

P.O. Box 1874-00621, Nairobi, Kenya

Tel: +254 725 34 39 32

Email: info@fwafrica.net

Copyright © All rights reserved. FW Africa. We are not responsible for content from external sites.